Targeted therapy of atopic dermatitis in children
- Authors: Botkina A.S.1, Dubrovskaya M.I1, Khandamirova O.O1
-
Affiliations:
- Pirogov Russian National Research Medical University
- Issue: Vol 29, No 8 (2022)
- Pages: 63-68
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/321045
- DOI: https://doi.org/10.18565/pharmateca.2022.8.63-68
- ID: 321045
Cite item
Open Access
Access granted
Abstract
Atopic dermatitis (AD) is one of the most common dermatoses affecting up to 20% of children and 10% of the adult population of the planet. Recently, there has been a significant increase in the incidence and an increase in severe, treatment-resistant forms of the disease, which inevitably leads to polypharmacy. According to modern concepts, the immune dysregulation manifested, in particular, by hyperproduction of interleukin-4 (IL-4) and IL-13, plays a central role in the pathogenesis of dermatosis. The achievements of modern medical science have made it possible to use targeted therapy for the treatment of AD and to have a selective effect on the pathogenesis of the disease, suppressing or significantly reducing allergic inflammation in the skin. Dupilumab, the first and only biologic drug approved by the FDA for the treatment of moderate to severe AD in children, targets the signaling of key cytokines, IL-4 and IL-13. The use of genetic engineering technologies in the treatment of AD was a breakthrough, allowing not only to mask the symptoms of the disease, but also to change the its course.
Full Text
About the authors
Aleksandra S. Botkina
Pirogov Russian National Research Medical University
Email: botkina@gmail.com
Cand. Sci. (Med.), Associate Professor at the, Department of Hospital Pediatrics n.a. Acad. V.A. Tabolin, Faculty of Pediatrics Moscow, Russia
M. I Dubrovskaya
Pirogov Russian National Research Medical UniversityMoscow, Russia
O. O Khandamirova
Pirogov Russian National Research Medical UniversityMoscow, Russia
References
- Европейское руководство по лечению дерматологический заболеваний. Под ред. А.Д. Кацамбаса, Т.М. Лотти. М., 2009. 724 с.
- Barbarot S., Auziere S., Gadkari A. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73:1284-93. doi: 10.1111/all.13401.
- Skolnik N.S., Carnahan S.P Primary care of asthma: new options for severe eosinophilic asthma. Curr Med Res Opin. 2019;3 doi: 10.1080/03007995.2019.1595966.
- Bantz S.K., Zhu Z., Zheng T. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. J Clin Cell Immunol. 2014;5(2):202. doi: 10.4172/21559899.1000202.
- Whiteley J, Emir B, Seitzman R., Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1645-51. doi: 10.1080/03007995.2016.1195733.
- Jang H.J., Hwang S., Ahn Y, et al. Family quality of life among families of children with atopic dermatitis. Asia Pac Allergy. 2016;6:213-19. doi: 10.5415/apallergy.2016.6.4.213.
- Shirakawa T., Deichmann K.A., Izuhara K., et al. Atopy and asthma: genetic variants of IL-4 and IL-13 signalling. Trend Immunol. 2000;21(2):60- doi: 10.1016/S0167-5699(99)01492-9.
- Shamoun L., Skarstedt M., Andersson R.E., et al. Association study on IL-4, IL-4Ralpha and IL-13 genetic polymorphisms in Swedish patients with colorectal cancer. Clin Chim Acta. 2018;487:101-6. doi: 10.1016/j.cca.2018.09.024.
- Chatila T.A.Interleukin-4 receptor signaling pathways in asthma pathogenesis. Trend Mol Med. 2004;10(10):493-99. doi: 10.1016/j.molmed.2004.08.004.
- Wollenberg A., Christen-Zach S., Taieb A., et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717-44. doi: 10.1111/jdv.16892.
- Будчанов Ю.И. Моноклональные антитела: от создания до клинического применения. Клиническая онкогематология. 2016;9(3):237-44. doi: 10.21320/2500.
- Skolnik N.S., Carnahan S.P Primary care of asthma: new options for severe eosinophilic asthma. Curr Med Res Opin. 2019;35(7):1309-18. doi: 10.1080/03007995.2019.1595966.
- Sanchez-Borges M., Capriles-Hulett A, Ortega-Martell J.A., Zubeldia I.A. New and Potential Treatments for Atopic Dermatitis: Biologicals and Small Molecules. Curr Allergy Asthma Rep. 2019;19(3):18. doi: 10.1007/s11882-019-0849-3.
- Круглова Л.С., Генслер Е.М. Атопический дерматит: новые горизонты терапии. Медицинский алфавит. Дерматология. 2019;1(7, 382):29-32. doi: 10.33667/2078- 5631-2019-1-7(382)-29-32.
- Thibodeaux Q., Smith M.P., Ly K., et al. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother. 2019;15(9):2129-39. doi: 10.1080/21645515.2019.1582403.
- Guttman-Yassky E., Bisso R., Ungar B., et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155-72. doi: 10.1016/j.jaci.2018.08.022.
- Harb H., Chatila Т.А. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5-14. doi: 10.1111/cea.13491.
- Matsunaga K., Katoh N., Fujieda S., et al. Dupilumab: Basic aspects and applications to allergic diseases. Allergol Int. 2020;69(2):187-96. doi: 10.1016/j.alit.2020.01.002.
- Thibodeaux Q., Smith M.P., Ly K., et al. A review of dupilumab in the treatment of atopic diseases. Hum Vaccin Immunother. 2019;15(9):2129-39. doi: 10.1080/21645515.2019.1582403.
- Распоряжение Правительства РФ от 12 октября 2019 г. № 2406-р [Электронный ресурс]. URL: http://base.garant.ru/72861778 (дата доступа/access date 16.05.2020).
Supplementary files
